IP Library Granted Patent US 8,703,706
Granted Patent B2
US 8,703,706 · App. 11/912,699 · Granted Apr 22, 2014

Closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit

Inventors: Anne Charlotte Arentsen (Holte, DK); Per Kaersgaard (Naerum, DK)
Assignee: Novo Nordisk Healthcare AG
A61K38/4846C07K14/745C12Y304/21021
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,706
App. No.
11/912,699
Granted
Apr 22, 2014
Kind
B2
Abstract

The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit.

Claims (26)

1. A process for the preparation of a concentrated solution of activated recombinant Factor VII polypeptide, said solution comprising in the range of from about 16 to about 25 mg of the activated Factor VII polypeptide per mL volume of a closed container, wherein, said process comprises the steps of:

(a) contacting a solution comprising a recombinant Factor VII polypeptide with an anion-exchange material under conditions which facilitate binding of a portion of said Factor VII polypeptide to said anion-exchange material said Factor VII solution having a pH in the range of 5.5-7.0, or a pH in the range of 8.5-9.5 with the presence of at least 15 mM Ca 2+ ;

(b) washing said anion-exchange material with a washing buffer having a pH in the range of 5.5-7.0; and

(c) eluting said anion-exchange material with an elution buffer having a pH in the range of 3.0-7.0, and comprising calcium ions (Ca +2 ) in a concentration of at least 15 mM; and collecting the eluate of the activated Factor VII polypeptide;

(d) loading at least a portion of the eluate into a container so that the container comprises in the range of from about 16 to about 25 mg of the activated Factor VII polypeptide per mL volume of the container;

(e) optionally lyophilizing the eluate; and

(f) sealing the container so as to provide a closed container.

2. Process according to claim 1 , wherein the elution buffer of step (c) comprises 15-50 mM Ca 2+ .

3. Process according to claim 1 , wherein the elution buffer of step (c) is a gradient buffer with respect to Ca 2+ wherein the initial concentration of Ca2+ is in the range of 15-20 mM and the final concentration of Ca2+ is in the range of 15-100 mM.

4. Process according to claim 1 , wherein the elution buffer of step (c) further comprises one or more mono-, di- or trivalent anions selected from the group of: chloride, acetate, malonate, phosphate, carbonate, sulphate, and nitrate.

5. Process according to claim 3 , wherein the elution buffer of step (c) comprises chloride anions (Cl − ) in a concentration of 100-800 mM.

6. Process according to claim 1 , wherein the elution buffer of step (c) has an ionic strength of 100-1000 mM.

7. A process according to claim 1 , wherein the washing buffer of step (b) further comprises salts corresponding to an ionic strength of 40-250 mM.

8. A process according to claim 1 , wherein the anion-exchange material of step (a) is a hydroxyapatite material.

9. A method for obtaining a concentrated solution of an activated recombinant Factor VII polypeptide, said method comprising the steps of:

(a) contacting a solution comprising a recombinant Factor VII polypeptide with an anion-exchange material under conditions which facilitate binding of a portion of said Factor VII polypeptide to said anion-exchange material, said Factor VII solution having a pH in the range of 5.5-7.0, or alternatively a pH in the range of 8.5-9.5 with the presence of at least 15 mM Ca 2+ ;

(b) washing said anion-exchange material with a washing buffer having a pH in the range of 5.5-7.0; and

(c) eluting said anion-exchange material with an elution buffer having a pH in the range of 3.0-7.0, and comprising calcium ions (Ca 2+ ) in a concentration of at least 15 mM; and collecting the eluate of the activated Factor VII polypeptide;

wherein the concentrated solution of the activated Factor VII polypeptide obtained has a concentration from about 16 to about 25 mg per mL.

10. Method according to claim 9 , wherein the elution buffer of step (c) comprises 15-50 mM Ca 2+ .

11. Method according to claim 9 , wherein the elution buffer of step (c) is a gradient buffer with respect to Ca 2+ wherein the initial concentration of Ca2+ is in the range of 15-20 mM and the final concentration of Ca2+ is in the range of 15-100 mM.

12. Method according to claim 9 wherein the elution buffer of step (c) further comprises one or more mono-, di- or trivalent anions selected from the group of: chloride, acetate, malonate, phosphate, carbonate, sulphate, and nitrate.

13. Method according to claim 12 , wherein the elution buffer of step (c) comprises chloride anions (Cl − ) in a concentration of 100-800 mM.

14. Method according to claim 9 , wherein the elution buffer of step (c) has an ionic strength of 100-1000 mM.

15. Method according to claim 9 , wherein the washing buffer of step (b) further comprises salts corresponding to an ionic strength of 40-250 mM.

16. Method according to claim 9 , wherein the anion-exchange material of step (a) is a hydroxyapatite material.

Assignments (2)
CHANGE OF ADDRESS Recorded Jun 19, 2013
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 030653/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2008
From: ARENTSEN, ANNE CHARLOTTE; KAERSGAARD, PER
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 020948/0419 →
Priority Claims (1)
DK 2005 00619 · Apr 28, 2005 · national
Continuity (2)
Provisional Application 60679041 · May 9, 2005
Related Publication 20080206225A1 · Aug 28, 2008